Abstract

This article has been retracted at the request of the author.
I would like to formally request that the article entitled, “Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant” (volume 55, pp. e30-e32; doi: 10.3928/01913913-20180806-01) be retracted.
Although our group was involved in the initial treatment of the patient described, we were not involved in the Investigational New Drug Applications administered by the Indiana Hemophilia & Thrombosis Center and Vanderbilt University after the patient’s family moved out of state, and therefore do not have access to the full details of the drug data from the two biopharmaceutical companies that manufacture these products.
Zaina Nabil Al-Mohtaseb, MD
doi:10.3928/01913913-20181220-02

Abstract

This article has been retracted at the request of the author.
I would like to formally request that the article entitled, “Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant” (volume 55, pp. e30-e32; doi: 10.3928/01913913-20180806-01) be retracted.
Although our group was involved in the initial treatment of the patient described, we were not involved in the Investigational New Drug Applications administered by the Indiana Hemophilia & Thrombosis Center and Vanderbilt University after the patient’s family moved out of state, and therefore do not have access to the full details of the drug data from the two biopharmaceutical companies that manufacture these products.
Zaina Nabil Al-Mohtaseb, MD
doi:10.3928/01913913-20181220-02

This article has been retracted at the request of the author.
I would like to formally request that the article entitled, “Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in an 8-Week-Old Female Infant” (volume 55, pp. e30-e32; doi: 10.3928/01913913-20180806-01) be retracted.
Although our group was involved in the initial treatment of the patient described, we were not involved in the Investigational New Drug Applications administered by the Indiana Hemophilia & Thrombosis Center and Vanderbilt University after the patient’s family moved out of state, and therefore do not have access to the full details of the drug data from the two biopharmaceutical companies that manufacture these products.
Zaina Nabil Al-Mohtaseb, MD
doi:10.3928/01913913-20181220-02